PAMIFOS

This brand name is authorized in Finland, Poland

Active ingredients

The drug PAMIFOS contains one active pharmaceutical ingredient (API):

1 Pamidronate Disodium
UNII 8742T8ZQZA - PAMIDRONATE DISODIUM

The principal pharmacologic action of pamidronic acid is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronic acid adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone.

Read about Pamidronate Disodium

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
M05BA03 Pamidronic acid M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 017700, 017766
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100108059, 100108065, 100108071

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.